CRISPR Therapeutics AGCRSPNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-16.9%
5Y CAGR+3.7%
Year-over-Year Change
Research and development spending
3Y CAGR
-16.9%/yr
vs +41.9%/yr prior
5Y CAGR
+3.7%/yr
Recent deceleration
Acceleration
-58.8pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $265.33M | -17.3% |
| 2024 | $320.65M | -17.2% |
| 2023 | $387.33M | -16.1% |
| 2022 | $461.64M | +35.6% |
| 2021 | $340.57M | +53.8% |
| 2020 | $221.38M | +23.4% |
| 2019 | $179.36M | +57.6% |
| 2018 | $113.77M | +63.0% |
| 2017 | $69.80M | +65.3% |
| 2016 | $42.24M | - |